1 – 10 of 30
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
(
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
(
- Contribution to journal › Article
-
Mark
Race in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
2023) In Sociology of Health & Illness(
- Contribution to journal › Article
- 2022
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
(
- Contribution to journal › Article
-
Mark
The making of a Swedish strategy : How organizational culture shaped the Public Health Agency's pandemic response
(
- Contribution to journal › Article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
(
- Contribution to journal › Article
- 2021
-
Mark
Sweden
2021)(
- Chapter in Book/Report/Conference proceeding › Chapter in report
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter